Hybrid chalcone-pyrazoline derivatives: synthesis and in silico evaluation for anticancer potential
Future Medicinal Chemistry · 2025
DOI: 10.1080/17568919.2025.2561464 ↗Kurz gefasst
Fachartikel in der Zeitschrift Future Medicinal Chemistry, 2025. Verfasst von Purabi Saha und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, ISF College of Pharmacy, Moga, India. Hauptthemen laut MEDLINE: Antineoplastic Agents, Pyrazoles, Protein Kinase Inhibitors, Chalcone. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
AIM: This study aimed to design, synthesize, and evaluate a hybrid chalcone-pyrazoline derivatives as potential anticancer agents targeting B-Raf kinase in lung cancer. MATERIAL & METHODS: Chalcone-pyrazoline derivatives (PY1-PY10) were synthesized via Claisen-Schmidt condensation followed by cyclization, characterized using FT-IR, NMR, and LC-MS. In vitro cytotoxic activity was assessed against A549 human lung cancer cells using the MTT assay. Molecular docking studies were performed with B-Raf kinase (PDB ID: 2FB8) using Schrödinger software. ADME properties were predicted using SwissADME. RESULT: Compound PY7 exhibited the most potent cytotoxicity (IC₅₀ = 6.45 µM) and the highest docking score (-8.89 kcal/mol), showing strong binding interactions with GLN530 in B-Raf kinase. Structure Activity Relationship analysis revealed that electron-withdrawing para-nitro substituents enhanced potency, while electron-donating groups generally reduced activity. ADME profiling confirmed all compounds complied with Lipinski's Rule of Five, had high gastrointestinal absorption, and displayed favorable drug-likeness. CONCLUSION: The findings identify PY7 as a promising lead candidate with potent anticancer activity, strong B-Raf binding affinity, and favorable pharmacokinetics. This work supports chalcone-pyrazole scaffolds as viable templates for the development of novel targeted lung cancer therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Chemistry, ISF College of Pharmacy, Moga, India.
- Department of Pharmaceutical Analysis, ISF College of Pharmacy, Moga, India.
- Department of Pharmaceutical Sciences and Natural Products, School of Health Sciences, Central University of Punjab, Bathinda, India.
- Department of Pharmaceutics, ISF College of Pharmacy and Research, Moga, India.
- Department of Pharmaceutical Chemistry and Analysis, ISF College of Pharmacy, Moga, India.
ORCID-Profile: Purabi Saha, Azra Yasmin, Ritesh Jha, Aarti Passi, Vikramdeep Monga, Shammy Jindal, Kamya Goyal
Zitieren
APA
Saha, P., Yasmin, A., Jha, R., Passi, A., Monga, V., Jindal, S., & Goyal, K. (2025). Hybrid chalcone-pyrazoline derivatives: synthesis and in silico evaluation for anticancer potential. Future Medicinal Chemistry. https://doi.org/10.1080/17568919.2025.2561464
Vancouver
Saha P, Yasmin A, Jha R, Passi A, Monga V, Jindal S, et al. Hybrid chalcone-pyrazoline derivatives: synthesis and in silico evaluation for anticancer potential. Future Medicinal Chemistry. 2025. doi:10.1080/17568919.2025.2561464
BibTeX
@article{Saha2025,
author = {Saha, Purabi and Yasmin, Azra and Jha, Ritesh and Passi, Aarti and Monga, Vikramdeep and Jindal, Shammy and Goyal, Kamya},
title = {Hybrid chalcone-pyrazoline derivatives: synthesis and in silico evaluation for anticancer potential},
journal = {Future Medicinal Chemistry},
year = {2025},
doi = {10.1080/17568919.2025.2561464}
}
EUVIMED